news
New polymer coating for improved cancer targeting of nanomedicine
A new study published in the Journal of Controlled Release reports some intriguing developments in the tumour-targeting delivery of nanomedicines.
List view / Grid view
Cancer
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz-300x278.jpg)
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz.jpg)
news
Bayer tops out new Leverkusen production facility
The new €275 million facility will be used to manufacture medicinal products for cancer and cardiovascular diseases and is scheduled to be ready for operation in 2024.
news
Rise of biologics set to continue, says report
According to a new report, biologics are forecast to have $120 billion greater sales than small molecules by 2027.
article
Precision medicine for complex chronic diseases: how near are we?
Targeting medicines against the genetic and molecular drivers of lung, breast and other tumours has helped transform cancer care for many patients, yet precision medicine for complex chronic diseases has lagged behind. Maria Orr, Adam Platt and Ben Challis, from BioPharmaceuticals R&D at AstraZeneca, explain why this is changing for…
article
Engaging the innate immune system to fight cancer effectively
Most therapeutic approaches in immuno-oncology focus on targeting the adaptive immune system; innate immunity has only recently gathered momentum. One of the most potent receptors for activating innate immune cells such as natural killer cells and macrophages is CD16A. Addressing this target mimics the body’s natural defense against potential threats,…
article
Drug Formulation In-Depth Focus 2022
Features in this in-depth focus highlight developments in the MRI contrast agent space, explore the development of precision medicine for chronic diseases and explain why immunotherapies should engage the innate immune system in the fight against cancer.
news
Designed for success – new SNA vaccine proves highly effective in mice
A team of scientists has developed a spherical nucleic acid (SNA) vaccine, which has demonstrated high efficacy as a COVID-19 therapy, as well as an anti-cancer treatment in rodents.
news
Implantable technology could enable in vivo CAR T therapy
Pre-clinical research demonstrates the potential of a new implantable biotechnology called MASTER to produce and release CAR T cells in vivo.
news
Could CAR T therapies be manufactured in one day?
New pre-clinical research suggests a 24-hour manufacturing process that produces fewer, more potent CAR T cells could be the key to both reducing production timelines and improving patient access to cell therapies.
news
US FDA calls for 34 percent increase in funding
The FDA has requested a 2023 budget of $8.4 billion from the US Government, a $2.1 billion increase in funding from 2022.
![Merck logo atop Merck Research Laboratories campus in Silicon Valley [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-5-300x278.jpg)
![Merck logo atop Merck Research Laboratories campus in Silicon Valley [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-5-e1648202271156.jpg)
news
Dr Roy Baynes to retire from Merck
Dr Roy Baynes, Merck’s head of Global Clinical Development (GCD) and Chief Medical Officer, will retire in July.
news
Novasep announces €5.1mn investment to grow HPAPI production
The €5.1 million will add a new chemical synthesis workshop for HPAPIs, expanding Novasep’s HPAPI production capacity at its Le Mans site in France.
article
Challenges in downstream purification of advanced therapies
John Liddell, Chief Technologist at the Centre for Process Innovation (CPI), writes about the challenges associated with gene therapy products, which constitute a major portion of the overall cell and gene therapy market.
article
Phase I oncology studies: rule- versus model-based design
In this article, Karen Ooms, Head of Statistics at Quanticate, compares the rule- and model-based approaches to Phase I trial design, exploring their benefits and weaknesses in defining maximum tolerated dose for oncology products.
news
MCAP for top bio/pharma companies reached $3.4 trillion in 2021
Market capitalisation (MCAP) for the top bio/pharma companies grew 24.9 percent in 2021, with BioNTech and Moderna entering the top 20 for the first time.
